The trial aims to assess the safety and efficacy of tralokinumab 300mg administered biweekly as a single agent.

LEO Pharma has reported outcomes from the 16-week interim analysis of the Phase IIIb ADHAND trial of tralokinumab for hand atopic dermatitis (AD).

Treatment with dupilumab is associated with weight gain in about two thirds of adults with atopic dermatitis over 3-6 months, according to a retrospective study.

Promising Psoriasis Pipeline Therapies such as Hypericin, EDP1815, Cetaphil, AX-158, HAT1 topical solution, Calcipotriol, ARQ ...

Advancements in itch therapeutics have evolved rapidly, offering patients with various itch-driven diseases multiple options that target the source of their itch. Itch exists on a spectrum, according ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Medically reviewed by Jurairat J. Molina, MD Caffeine is a substance that raises alertness and boosts energy. Most adults can safely consume up to 400 milligrams of caffeine daily, equivalent to about ...

Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid. Click here to find out why AMGN stock is a Buy.